Drug Trial Radar · NCT06724549
The Effect of Food on the Pharmacokinetics of BN104 Tablets
Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 12, 2025
Primary completion
Feb 13, 2025
Study completion Feb 13, 2025
Sponsor
- Lead sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of the clinical trial is to evaluate the effect of food on the Pharmacokinetics of BN104 tablets in healthy subjects. The main questions it aims to answer are: Whether the pharmacokinetic characteristics of BN104 tablets will be affected by food? How well is the safety and tolerability of BN104 tablets in healthy subjects? To preliminarily evaluate the effect of BN104 on the QTc interval.
Conditions
- Health Subjects
Interventions
BN104Drug
This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak concentration (Cmax)Time frame: 2 weeks
- Auc(0-last)Time frame: 2 weeks
- Auc(0-∞)Time frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.